SUMMARY-F344 rats received grafts of syngeneie 13762 mammary adenocareinoma eells previously admixed with either Iiving BCG or killed Corynebacterium parvum administered sc or intradermally (id). Animals given id transplants of tumor eells admixed with either BCG or killed C. parvum exhibited tumor growth for an average of 10 days, then regression in size and rejection of the tumor nodules. Lesions were found in rats given sc transplants of tumor eells admixed with the killed mieroorganism for an average of 13 days with the same results. When live BCG was added to the sc transplants, aeeelerated rates of "tumor growth and early death were noted, eompared with the group reeeiving tumor eells alone sc. Suppressed rates of tumor growth and prolonged survival were observed in the groups reeeiving id inoculations of tumor eells followed by treatment with killed C. parvum administered weekly ip or id 1 em away and around the growing tumor. On the other hand, weekly treatment of BCG injected either ip or id 1 em away and around the growing tumor resulted in aceelerated rates of tumor growth and early death. Animals exhibiting C. parvum or BCG-mediated tumor rejection displayed tumor-speeifie protection to sc challenge injections of the eell line initially used, but they died with growing tumors and metastases when ehallenged with tumor eells of an antigenieally different line syngeneie to F344 rats. Mieroscopie examination of histologie sections of tumors formed from id inoculations of tumor eells admixed with either BCG or killed C. parvum revealed a nonspecifie infiltrate of maerophages and polymorphonuelear leukoeytes in the tumor, whereas seetions of tumors formed from sc grafts of eells admixed with killed C. parvum revealed a specific organized infiltrate of mostly maerophages around the tumor follieles.-J Natl Cancer Inst 56: 985-989, 1976. Optimal results with the use of living Myeobacterium bovis (strain BCG) in experimental cancer immunotherapy were first reported by Zbar and co-workers (1), who observed that BCG totally prevented the growth of tumor cells in recipients, when it was admixed with living tumor cells before they were inoculated intradermally (id) [the id site prornotes tumor growth and regression (2) ]. Furthermore, intratumor infection with BCG into growing intradermal tumor nodules also resulted in regression and complete rejection (3) 4). A completely different phenomenon was observed in animals receiving sc injections (the sc site promotes early dissemination) of tumor cells as an inoculum containing killed Corynebacterium parvum. These animals exhibited expected tumor growth (at the injection site) for approximate1y 2 weeks. Thereafter, tumor-specific rejection of the growing tumors occurred in all the animals (5) . Subsequent studies revealed that intratumor-permeating injections of killed C. parvum also resulted in rapid rejection of subcutaneously growing tumors in syngeneic animals (6, 7) , and the conferred immune response was effective in protecting these animals against progressive growth of potentially lethaI metastases present at the time of therapy. The studies presented here, in which living BCG and killed C. parvum are used, compare the rejection of tumors syngeneic to F344 rats.
MATERIALS AND METHODS
Rats.-Female 40-to 50-g F344 rats were obtained rom the Charles River Breeding Laboratories (Wilml?gton, Mass.) and kept under normal laboratory conditions.
C. parvum.-Preparation of killed C. parvum were obtained from Institut Merieux (Lyon, France). The method of preparation was described in (5) .
. Mycobacterium bovis. Evaluation 0/ tumor growth.-After transplanting the tumor ceIls, we inspected the animals daily and measured t?e palpable tumors with a caliper twice weekly. Tumor size was expressed as the average of two diameters (perpendicular to each other). Animals in the control and experimental groups were compared at the end of the experiment, and the differences between the groups were tested for significance by the paired t-test. a) DMB 14 mammary adenocarcinoma, a dimethylcholanthrene-induced carcinoma emerging in a,n F344 female rat, has been passed serially without loss of characteristics. The 100% lethal sc dose in recently weaned animals was 10 5-106 tumor cells, and the animals died with growing tumors and metastases in 50-70 days.
b) The 13762 mammary adenocarcinoma syngeneic to F344 rats was obtained from the Mason Research Insti~ute (Worcester, Mass.) and passed serially in syngenelC females without loss of its characteristics, which were described (7) . Sensitization of rats to an irradiated tumor of one tumor cell line resul ts in protection against subsequent injections of tumor cells only of that line.
Tumor implantation.-Using aseptic techniques, we removed tumor tissue from recently killed donor animals, cut it into pieces of various sizes, and trimmed connective tissue and any grossly apparent necrotic or hemorrhagic material from each piece. The glistening portions were then cut into 1-to 2-mm 3 slices. Suspensions of tumor cells in medium 199 were obtained by mild manipulation of the tumor slices on surgical tantalum gauze; they were washed 3 times (IOx vol medium 199; 500xg for 10 min) and then resuspended in the medium. The final suspension was allowed to set for 2 minutes to sediment the larger clumps of cells, and then the supernatant was removed and readjusted to a cell count of approximately 2.5 X 10 7 cells Im!.
Sixty previously unsensitized rats were separated into groups of 10 each. The size of each tumor-cell inoculum dose was 5 X 10 6 13762 cells injected in a volume of 0.2 ml. All rats of a group each received one of the following: 1) 13762 cells id; 2) 13762 cells sc; 3) 13762 cells admixed with 10 6 BCG organisms id; 4) 13762 cells admixed with 10 6 BCG organisms sc; 5) 13762 cells admixed with 1 mg C. parvum id; 6) 13762 cells admixed with 1 mg C. parvum.
RESULTS
The groups of rats receiving id inoculations of tumor cells mixed with killed C. parvum or live BCG exhibited minimal amounts of tumor growth for about 10 days; then the tumors disappeared in an animals (text- fig. 1 ). The group receiving sc inoculations of tumor cells admixed with C. parvum had normal rates of tumor growth for approximately 13 days; an the tumors subsequently regressed and disappeared. The group receiving tumor cells admixed with BCG sc, when compared with the group receiving only tumor cells, showed slightly enhanced rates of neoplastic growth and died with developing tumor and metastases in 30-40 days. Those animals receiving the 13762 cells alone sc died in 40-52 days with growing tumor and metastases, whereas the group receiving id injections of tumor cells alone died with growing tumors and metastases in 52-65 days.
Sixty days later, each group of animals surviving in the above experiments were separated into subgroups of 5 animals each. Groups of 5 of similar ages and previously unsensitized rats served as controls. tion) of 13762 cells were protected. The remaining 3 rats died with slow-growing tumors and metastases. Unsensitized rats given 10 7 and 5 X 10 8 13762 cells sc died predictably with growing tumors and metastases. These experiments were repeated with similar results (I of 5 rats survived after reinjection of 5 X 10 8 tumor cells after inoculation of tumor cells mixed with BCG).
Subsequently, 3 of the rats (8jgroup) received one of the following id: 1) 5 X 10 6 13762 cells; 2) 5 X 10 6 13762 cells admixed with 1 mg killed C. parvum; or 3) 5 X 10 6 13762 cells admixed with BCG (10 6 organisms). Similarly, 3 other groups of rats received sc injections of the inocula described above. The animals were killed at 10 days, and the tumors were excised and placed in 10% formalin in Hanks' buffer for 24 hours. Microscopic evaluation of histologie seetions (Giemsa stain) from the controls revealed an absence of cellular infiltrate. Intradermally growing tumors formed from inoculations of BCG or C. parvum had nonspecific macrophage infiltrates, but no lymphocytes were observed. We found that the subcutaneously growing tumors formed from inoculations of tumor cells and C. parvum had an organized infiltrate of macrophages around each tumor follicle, whereas those formed from sc inoculation of cells and BCG revealed only a scanty, unorganized infiltrate.
We performed the following experiment to evaluate the nature of tumor rejection: Ten groups (10 animals/ group) of previously unsensitized rats received id injections of one of the following: I) 5x 10 6 13762 cells mixed with 10 6 BeG organisms (groups 1 and 2); 2) 10 7 DMB 14 cells mixed with 10 6 BCG organisms (groups 3 and 4); 3) 5x 10 6 13762 cells mixed with I mg killed C. parvum (groups 5 and 6); 4) 10 1 DMB 14 cells mixed with 1 mg killen C. parvum (groups 7 and 8); 5) 5 X 10 6 13762 cells; or 6) 10 7 DMB 14 cells. All the animals in the groups receiving tumor cells admixed with either BCG or C. parvum formed tumors at the site of injection that were later rejected as described previously; rats given tumor cells alone died with growing tumors and metastases (table 2) .
Three months after the start of the above experiment, each of the surviving groups was separated into 2 subgroups of 5 animals each. Four groups (5 animalsjgroup) of previously unsensitized rats of similar ages served as controls. After rejection of tumors formed from inocula of cells admixed with BCG or C. parvum, groups of rats All the animals of the groups that showed BCGmediated tumor rejection (like the controls) died after injection of the antigenically different tumor eells.
The following experiment was performed in order to observe the effeet of BCG and C. parvum (injeeted at sites remote from the growing tumors) on recipients of tumor cell grafts. Seventy (7 groups, 10jgroup) previously unsensitized rats received id inoculation of one of the following: I) 5x 10 6 13762 eells alone; 2) 5X 10
6 13762 cells admixed with 1.0 mg C. parvum; 3) 5 X 10 6 13762 cells followed by weekly ip injeetions of C. parvum; 4) 5 X 10 8 13762 eells followed by weekly ip injections of BCG (10 6 organisms): 5) 5x 10 8 13762 cells admixed with BCG (10 8 organisms); 6) 5 X 10 6 13762 eells followed by weekly id injection of living BCG (10 6 organisms I cm away and around the injeetion site and growing tumor): and 7) 5 X 10 6 13762 cells followed by weekly injeetions of killed C. parvum administered id 1 cm away and around the injection site and growing tumor. All injections of BCG or C. parvum were commenced a week after inoeulation of tumor cells and were continued weekly until death.
The results illustrated in text-figure 2 revealed that tumor growth in all animals receiving tumor eells admixed with BCG or C. parvum was as expected for approximately 12 days, then the tumors disappeared. In the 10 rats given id inoculations of tumor cells followed by weekly id injectlons of C. paruum. 1 cm away and around the growing tumor, lesions grew in 3 and then were rejected. The remaining 7 exhibi ted suppressed rates of tumor growth and prolonged survival (range, 108-120 days). Suppressed tumor growthand prolonged survival were also observed in all animals receiving weekly ip injections of C. parvum after id grafts of tumor cells (range, 68-82 days). All rats given id grafts first and then id injections of BCG 1 cm away and around the growing tumor died (range, 50-60 days) with growing tumors and metastases; their survival rates were comparable to the controls (range, 48-60 days). On the other hand, eompared withcontrols the growth rates of tumors in rats reeeiving id inoculations of tumor cells before weekly ip injeetions of BCG were accelerated and early death ensued (range, 42-56 days), Gross examination by autopsy revealed that animals treated with ip doses of killed C. parvum had considerably fewer peritoneal and pulmonary metastases, whereas the rats treated with BCG had more metastatic nodules when compared with their respective eontrols. Similar results were observed when these experiments were repeated (5 of 10 rats receiving id grafts of 13762 tumor cells before a weekly id injection of killed C. parvum was administered 1 cm away and around the growing tumor rejected tumors and survived tumor-free),
DISCUSSION
We found that tumor growth was suppressed in F344 rats after id inoculation of syngeneic 13762 mammary adenocarcinoma cells admixed with either living BCG or killed C. parvum. Tumor cells admixed with killed C. parvum and injected sc also resulted in rejection of the tumors formed from these grafts by the recipients. Furthermore, groups of rats bearing id tumor cell grafts exhibited suppressed rates of tumor growth and prolonged survival after being given killed C. parvum either ip or id 1 cm away and around the growing tumors. However, in similar experiments when living BCG was substituted for therapy (i.e., sc injections of tumor cells admixed with BCG; id inoculation of tumor cells before ip injections of BCG; and id inoculation of tumor cells and BCG 1 cm away and around the growing tumor), there was a lack of protection since these recipients died early with growing tumors and metastases. Animals showing tumor rejection mediated by killed C. parvum or living BCG exhibited tumor-specifie protection to the sensitizing cell line. In addition, animals having C. parvum-mediated tumor rejection exhibited protection to larger doses of challenge tumor cell grafts than did those showing BCG-mediated tumor rejection.
The function of macrophages in tumor rejection associated with immunoprotection was implied, since microseopie examination of histologie sections of tumors from animals displaying C. parvum or BCG-mediated tumor rejection revealed a nonspecific infiltrate of mostly granulocytes and macrophages in intradermally growing tumor nodules. The tumors regressing from initial sc transplants of eells admixed with C. parvum revealed a specific infiltration of many macrophages, polymorphenuclear granulocytes, and some lymphocytes around the tumor follicles. Minimal nonspeeific infiltrate of mostly granulocytes and macrophages was seen in similar sections of tumors arising in animals given sc grafts of tumor cells admixed with BCG.
Although many similarities exist between living BCG and killed C. parvum in experimental cancer immunotherapy, there are also notable differences. In previous studies, Zbar (8) reported that he had optimal results with BCG with the use of a) living BCG, b) dose contaet between tumor eells and BCG, c) id administration, and d) a host capable of expressing a eell-mediated immune response. If these requirements were not observed, administration of BCG resulted in acceleration of tumor growth (9). In addition, C. parvum vaccine was effective in the treatment of subcutaneously growing tumors and appeared to enhance host resistance toward tumors and metastases after administration at a site other than that of a growing tumor (5-7). It was also benefieial in mice immunocompromised by thymectomy and treatment with rabbit antiserum to mouse thymocytes (10). Furthermore, C. parvum was effective in the treatment of metastases in experimental animals (6, 7, (11) (12) (13) (14) (15) (16) .
Animals reeeiving administrations of live BeG or killed C. parvum reflected an intense stimulation of the reticuloendothelial system and phagocytosis (17-19), steps that are essential for the induction of tumor-speeific immune responses (20-24) . Both immunostimulant adjuvants also stimulate recruitment of lymphocytes into lymphoid structures in experimental animals (25-27). In addition, they induce thymus-dependent and .independent lymphocyte activity (7, 20, 21, (28) (29) (30) (31) (32) (33) (34) (35) and also primitive surveillance mechanisms (36-39) effective in graftversus-host reactions. These studies also revealed that killed C. parvum was a more potent immunostimulant than BCG. Lamensans and co-workers (40) reported that injections of killed C. parvum and lymphoma cells in AKR mice resulted in 50 and 83% survival, respectively, in syngeneic AKR and AKR (CBA/T6)F 1 mice, which suggested that there was also augmentation of the aIlogeneic effect. Furthermore. unlike observations with BCG, killed C. parvum was effective in thymectomized or T -eell depleted animals (10, 41).
In some of our recent experiments, we compared the efficaey of intratumor administration of live BCG and killed C. parvum in groups of rats bearing tumors at either intradermal or subcutaneous sites. Preliminary results indicate that BCG was effective only in the treatment of intradermally growing tumors and had no effect on rnetastases. Intratumor administration of tumors growing in rats at the intradermal and subcutaneous sites resulted not only in rejection of the growing tumors, but the conferred response was effective (unlike BCG) in the rejection of potentially lethai metastases.
Remarkable progress has been made in the field of cancer therapy since the first re ports of experimental immunotherapy with the use of living BCG and killed C. parvum (42-45). Although both immunopotentiating substances have been employed in clinieal cancer immunotherapy (46, 48), additional information is essential from similar experiments to eletermine the efficacy of these vaccines. 
